Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia that is developing and commercializing antibodies to address a wide range of applications in the diagnosis and treatment of cancer.

Biosceptre’s Vision is to make a significant contribution to the diagnosis and treatment of cancer worldwide and provide a significant return to their shareholders.  This will be achieved through advancing development of various applications of their proprietary cancer marker / target to the point where they can be acquired and commercialized by major global pharmaceutical companies.

P2X₇ is a major cellular receptor responsible for normal programmed cell death.  Biosceptre’s technology is based on the fundamental discovery of a subtly changed non-functional form of P2X₇ (nf-P2X₇) that is found on cells of all solid tumors, but not on cells of normal tissues.  Biosceptre has patents around P2X₇ and nf-P2X₇ as a diagnostic marker and therapeutic target in human and animal cancers.

The Company has developed and continues to develop an inventory of antibodies and antibody constructs which specifically target the non-functional forms of the P2X₇ receptors which are found on the majority of all cancer types and have application in both therapeutic and diagnostic areas:

Therapeutics

Systemic Therapeutics

Whole antibodies and antibody constructs are being developed as immunotherapeutics to target a wide range of primary human cancer types as well as secondary metastatic tumors.

Topical or Local Therapeutics

Antibodies are being formulated for local and/or topical applications targeting easily accessible skin cancers.

Vaccine

The potential exists to develop a vaccine against the nf-P2X₇ receptors to target cancer cells remaining after treatment of a primary tumour.  It would also prevent the growth of new cancer cells expressing this receptor.

Diagnostics

IHC: Immunohistochemistry Diagnostic Tests on Tissue Samples
This test is performed on tissue samples collected during routine biopsy procedures.  Development of the test is directed towards those indications in which there is significant competitive and practical clinical advantage for its use.  The lead indication is for use in prostate cancer.

Fluid Based Diagnostics
Research into the development of a test to detect the presence of P2X₇ receptor shed into the body fluids of cancer patients is being conducted.  The body fluids include plasma, serum, urine and reproductive secretions.

In Vivo Imaging
Antibody constructs are being developed for injection into suspected cancer patients to enable the location of the primary and/or secondary tumours to be determined using whole body scans and imaging technology.

Animal Health

The diagnostic and therapeutic applications for human cancers are equally applicable to cancers in companion and domestic animals.  All animal cancers which have so far been investigated have shown the presence of the nf-P2X₇ receptor.

Biosceptre’s discoveries and technologies are already generating strong interest from international diagnostic and pharmaceutical companies.  With cancer being the second leading cause of death worldwide, and the disease with the highest unmet medical need, Biosceptre’s technology has the potential to change the way cancer is diagnosed and treated worldwide, offering unparalleled benefits to patients, doctors and investors alike.

To view a short animation of Biosceptre’s technology, click here.